What is the main difference between CJC-1295 and sermorelin?

Half-life. Sermorelin has a half-life of about 10 to 20 minutes — quick pulse, quick gone. CJC-1295 (with the DAC modification) has a half-life of about 8 days, which is why it is dosed once or twice weekly instead of nightly.

Is CJC-1295 stronger than sermorelin?

Not exactly stronger — longer-acting. CJC-1295 maintains an elevated baseline growth-hormone signal over days. Sermorelin produces a single pulse each dose. Different clinical effect, not different potency.

Which one is more researched in humans?

Sermorelin has decades of human use — the branded version (Geref) was FDA-approved in 1997 for pediatric growth hormone deficiency before being discontinued for commercial reasons. Compounded sermorelin is not FDA-approved. CJC-1295 has a smaller but more recent human research base focused on adult GH replacement.

CJC-1295 vs sermorelin: comparing two GHRH analogs

Creator: Halftime Health
Keywords: CJC-1295 vs sermorelin, GHRH analog comparison, growth hormone releasing peptides

Two peptides that ask the pituitary the same question — but on very different schedules.

TL;DR

Sermorelin is short-acting (10–20 min half-life) and dosed nightly. CJC-1295 with DAC is long-acting (~8 day half-life) and dosed weekly.
Both work upstream — they ask the pituitary to release growth hormone. They do not contain growth hormone.
Choice depends on clinician preference, dosing convenience, and lab response, not on one being “better.”

What it is

Both are GHRH analogs (in plain English: lab-made copies of growth-hormone-releasing hormone, the natural signal the brain sends to the pituitary to release growth hormone). Sermorelin came first — it is a 29-amino-acid fragment of natural GHRH. CJC-1295 is a modified version designed to last much longer in the bloodstream. Think of sermorelin as a phone call that gets answered and ends. Think of CJC-1295 as a phone call that stays on the line for days.

How it works

A GHRH analog binds the GHRH receptor on the pituitary gland — the small pea-sized gland tucked under the brain. The pituitary then releases a pulse of growth hormone (GH). GH travels to the liver, which produces IGF-1, the molecule that actually drives most of the downstream tissue effects. Sermorelin produces one pulse and clears quickly. CJC-1295 with DAC (in plain English: a chemical add-on called Drug Affinity Complex that binds the peptide to albumin and extends its half-life from minutes to days) produces sustained signaling, per Teichman et al. 2006.

Who asks about it

People come to this question when they have already decided to explore growth-hormone-supporting peptides and are choosing between protocols. Nightly subcutaneous injections of sermorelin sound burdensome to some readers. Once-or-twice-weekly CJC-1295 sounds easier. The trade-off is the more sustained signal — which has different physiological consequences than the natural pulse pattern.

What the research says

Sermorelin has 25+ years of clinical experience and a peer-reviewed safety record for pediatric and adult use. CJC-1295 with DAC has a shorter but consistent literature, including Ionescu and Frohman, 2006 showing sustained IGF-1 elevation after a single dose. About 7 in 10 patients on either peptide show measurable IGF-1 increases at 12 weeks in clinical observation, though individual response varies.

What to know before considering it

Both peptides require physician supervision, baseline IGF-1 testing, and follow-up bloodwork. Both carry the same general contraindications — active cancer, uncontrolled diabetes, pregnancy. The sustained CJC-1295 signal raises questions about long-term receptor desensitization that the literature has not fully resolved.

The Halftime POV

We do not have a religious position on short-acting vs long-acting. Clinical fit drives the choice. Some readers tolerate nightly injections well and want the more natural pulse pattern of sermorelin. Others prefer weekly dosing for adherence. The decision belongs to the prescribing clinician, informed by labs and goals.

Related reading:

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.